Tilray (TLRY) Medical announced the final results of a new scientific study their team has supported titled, “Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting.” This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days. From 2016 to 2022, 147 participants were recruited. The study found that the cannabis extract significantly improved the rate of complete response-meaning no vomiting or use of additional medications-from 8% with placebo to 24% with THC: CBD. Other benefits included reduced nausea and fewer daily vomits. However, some side effects were noted, such as sedation, dizziness, and transient anxiety. Tilray Medical continues to transform lives by providing access to medical cannabis. Tilray is a leading provider of EU-GMP-certified medical cannabis products in over 20 countries. The company has supported medical trials globally, studying cannabis for various conditions, including pediatric epilepsy, cancer-induced nausea, and PTSD.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLRY:
- Rising High: Compass Pathways reports Q3 earnings
- Tilray’s Breckenridge announces collaboration with University of Colorado
- Tilray subsidiary releases new creation, Dad’s Stash Whiskey
- Rising High: RIV Capital provides update on revenue, synergy realization
- Tilray’s Blue Point announces men’s health awareness campaign